Home › Companies › NewAmsterdam Pharma Company N.V. › 2025-2026

NewAmsterdam Pharma Company N.V. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and NewAmsterdam Pharma Company N.V.’s Form 8-K, filed 2026-06-03 (Item 5.07 on EDGAR). Page generated 04 October 2026.

11Reported items
188Asset managers
1,570Fund votes
2026-06-02Meeting date

Proxy season: 2024-2025 2025-2026

Explore NewAmsterdam Pharma Company N.V. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by NewAmsterdam Pharma Company N.V.

These tallies are NewAmsterdam Pharma Company N.V.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-03 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

NewAmsterdam Pharma Company N.V. — official shareholder meeting results, meeting held 2026-06-02
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Proposal 2. The Company's shareholders approved the discharge from liability for the Company's directors with respect to the performance of their duties during the fiscal year ended December 31, 2025.	85,229,605	1,105,840	51,557	--	5,151,610	Majority: yes
Proposal 3. The Company's shareholders approved the instruction to Deloitte Accounts B.V.	91,502,529	4,636	31,447	--	--	Majority: yes
Proposal 4. The Company's shareholders ratified the selection by the Company's Audit Committee of Deloitte Accountants B.V.	91,502,639	4,618	31,355	--	--	Majority: yes
Elect Director: John W. Smither	85,375,639	956,620	54,743	--	5,151,610	Majority: yes
Elect Director: Janneke van der Kamp	75,256,863	9,899,189	1,230,950	--	5,151,610	Majority: yes
Proposal 6. The Company's shareholders approved the extension of authorization for the Board of Directors to issue Ordinary Shares (or rights to subscribe for Ordinary Shares) in the Company's capital, for a five-year period ending June 2,	59,539,558	26,801,646	45,798	--	5,151,610	Majority: yes
Proposal 7. The Company's shareholders approved the extension of authorization for the Board of Directors to limit or exclude pre-emption rights, for a five-year period ending June 2, 2031.	57,890,766	28,450,917	45,319	--	5,151,610	Majority: yes
Proposal 8. The Company's shareholders approved the ESPP.	86,221,442	139,927	25,633	--	5,151,610	Majority: yes
Proposal 9. The Company's shareholders approved the 2025 compensation of the Company's named executive officers by a non-binding, advisory ("Say-on-Pay") vote.	81,100,259	4,946,963	339,780	--	5,151,610	Majority: yes

Source: NewAmsterdam Pharma Company N.V., Form 8-K, filed with the SEC on 2026-06-03 — read the filing on EDGAR.

How asset managers voted at the NewAmsterdam Pharma Company N.V. 2025-2026 meeting

Each item below shows how the 188 asset managers that disclosed a NewAmsterdam Pharma Company N.V. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of NewAmsterdam Pharma Company N.V.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Non-binding, advisory vote to approve the 2025 compensation of named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 11 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 81,100,259AGAINST: 4,946,963

NewAmsterdam Pharma Company N.V.’s own tally for this item (“Proposal 9. The Company's shareholders approved the 2025 compensation of the Company's named executive officers by a non-binding, advisory ("Say-on-Pay") vote.”): 81,100,259 for, 4,946,963 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 116,641,656 outstanding shares: 70% for, 4% against (74% of the company cast a for/against vote).

The 185 asset managers below cast 95% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 94%

FOR: 94.4%AGAINST: 5.4%ABSTAIN: 0.2%NOT VOTED: 0.0%

Largest asset managers voting on “Non-binding, advisory vote to approve the 2025 compensation of named executive officers.” at NewAmsterdam Pharma Company N.V., 2025-2026
Asset manager	For	Against	Vote
Capital Group	22,284,429	0	For
Fidelity	11,631,425	217	For
RA CAPITAL MANAGEMENT, L.P.	9,542,296	0	For
FCPM III SERVICES B.V.	9,198,900	0	For
Bain Capital Life Sciences Investors, LLC	5,673,913	0	For
DEERFIELD MANAGEMENT COMPANY, L.P.	4,264,789	0	For
VIKING GLOBAL INVESTORS LP	4,203,567	0	For
Wellington	3,701,821	0	For
Janus Henderson	3,481,260	0	For
Polar Capital Holdings Plc	3,445,318	0	For
Vanguard	3,243,176	440	For
Duquesne Family Office LLC	3,070,146	0	For
Medicxi Ventures Management (Jersey) Ltd	2,674,182	0	For
WESTFIELD CAPITAL MANAGEMENT CO LP	1,811,766	15,980	For
AllianceBernstein	1,595,799	0	For
JENNISON ASSOCIATES LLC	0	1,570,542	Against
MAVERICK CAPITAL LTD	1,049,997	0	For
Aberdeen	1,004,689	0	For
Columbia Threadneedle	982,142	0	For
NEW ECONOMY FUND	957,477	0	For
American Century	0	869,137	Against
BNP Paribas Asset Management Holding S.A.	0	791,021	Against
Castle Hook Partners LP	790,685	0	For
Prudential/PGIM	64,490	611,111	Against
Rock Springs Capital Management LP	585,538	0	For

Showing the 25 largest of 185 asset managers. See all 185 in the interactive database.

2. EXTENSION OF AUTHORIZATION FOR THE BOARD OF DIRECTORS TO ISSUE ORDINARY SHARES (OR RIGHTS TO SUBSCRIBE FOR ORDINARY SHARES) IN THE COMPANY'S CAPITAL.

CAPITAL STRUCTUREMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

69% Majority: yes · of votes cast

FOR 69%AGAINST 31%

FOR: 59,539,558AGAINST: 26,801,646

NewAmsterdam Pharma Company N.V.’s own tally for this item (“Proposal 6. The Company's shareholders approved the extension of authorization for the Board of Directors to issue Ordinary Shares (or rights to subscribe for Ordinary Shares) in the Company's capital, for a five-year pe”): 59,539,558 for, 26,801,646 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 116,641,656 outstanding shares: 51.0% for, 23% against (74% of the company cast a for/against vote).

The 55 asset managers below cast 34% of the shares they voted on this item FOR (8,359,340 for, 16,574,601 against).

FOR 34%AGAINST 66%

FOR: 8,359,340 (33.5%)AGAINST: 16,574,601 (66.5%)

Largest asset managers voting on “EXTENSION OF AUTHORIZATION FOR THE BOARD OF DIRECTORS TO ISSUE ORDINARY SHARES (OR RIGHTS TO SUBSCRIBE FOR ORD” at NewAmsterdam Pharma Company N.V., 2025-2026
Asset manager	For	Against	Vote
Capital Group	1,638,968	7,692,745	Against
Fidelity	5,187,037	29,422	For
Vanguard	134,879	3,065,763	Against
Columbia Threadneedle	0	982,142	Against
NEW ECONOMY FUND	0	957,477	Against
Prudential/PGIM	611,111	64,490	For
JPMorgan	580,480	0	For
HARBOR FUNDS	0	474,913	Against
American Century	0	419,067	Against
AllianceBernstein	0	404,858	Against
BlackRock	0	340,338	Against
AB DISCOVERY GROWTH FUND, INC.	0	291,102	Against
Federated Hermes	0	238,053	Against
BNY Mellon	0	176,721	Against
Victory Capital	0	173,390	Against
Equitable	13,851	129,997	Against
FRANKLIN STRATEGIC SERIES	0	132,778	Against
ALPS ETF Trust	0	96,492	Against
Principal	0	87,095	Against
Lord Abbett	83,119	0	For
Bridge Builder Trust	0	81,840	Against
Eaton Vance	0	81,652	Against
Allspring	0	78,965	Against
Brighthouse	0	62,244	Against
OPTIMUM FUND TRUST	0	60,861	Against

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

3. Reappointment of the following individuals as non-executive directors of the Company until the annual general meeting set forth next to their name: Janneke van der Kamp until the 2030 annual general meeting

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%

FOR: 75,256,863AGAINST: 9,899,189

NewAmsterdam Pharma Company N.V.’s own tally for this item (“Elect Director: Janneke van der Kamp”): 75,256,863 for, 9,899,189 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 116,641,656 outstanding shares: 65% for, 8% against (73% of the company cast a for/against vote).

The 55 asset managers below cast 90% of the shares they voted on this item FOR (21,450,616 for, 2,472,463 against).

FOR 86%10%

FOR: 21,450,616 (86.0%)AGAINST: 2,472,463 (9.9%)ABSTAIN: 1,010,862 (4.1%)

Largest asset managers voting on “Reappointment of the following individuals as non-executive directors of the Company until the annual general ” at NewAmsterdam Pharma Company N.V., 2025-2026
Asset manager	For	Against	Abstain	Vote
Capital Group	9,331,713	0	0	For
Fidelity	5,216,459	0	0	For
Vanguard	3,200,642	0	0	For
Columbia Threadneedle	0	0	982,142	Abstain
NEW ECONOMY FUND	957,477	0	0	For
Prudential/PGIM	675,601	0	0	For
JPMorgan	580,480	0	0	For
HARBOR FUNDS	0	474,913	0	Against
American Century	0	419,067	0	Against
AllianceBernstein	0	404,858	0	Against
BlackRock	340,338	0	0	For
AB DISCOVERY GROWTH FUND, INC.	0	291,102	0	Against
Federated Hermes	238,053	0	0	For
BNY Mellon	176,721	0	0	For
Victory Capital	727	172,663	0	Against
Equitable	31,710	112,138	0	Against
FRANKLIN STRATEGIC SERIES	0	132,778	0	Against
ALPS ETF Trust	0	96,492	0	Against
Principal	0	87,095	0	Against
Lord Abbett	83,119	0	0	For
Bridge Builder Trust	81,840	0	0	For
Eaton Vance	81,652	0	0	For
Allspring	0	78,965	0	Against
Brighthouse	33,524	0	28,720	For
OPTIMUM FUND TRUST	60,861	0	0	For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

4. Reappointment of the following individuals as non-executive directors of the Company until the annual general meeting set forth next to their name: John W. Smither until the 2030 annual general meeting

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 85,375,639AGAINST: 956,620

NewAmsterdam Pharma Company N.V.’s own tally for this item (“Elect Director: John W. Smither”): 85,375,639 for, 956,620 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 116,641,656 outstanding shares: 73% for, 0.9% against (74% of the company cast a for/against vote).

The 55 asset managers below cast 100% of the shares they voted on this item FOR (24,905,221 for, 0 against).

FOR 99.8%

FOR: 24,905,221 (99.9%)ABSTAIN: 28,720 (0.1%)

Largest asset managers voting on “Reappointment of the following individuals as non-executive directors of the Company until the annual general ” at NewAmsterdam Pharma Company N.V., 2025-2026
Asset manager	For	Abstain	Vote
Capital Group	9,331,713	0	For
Fidelity	5,216,459	0	For
Vanguard	3,200,642	0	For
Columbia Threadneedle	982,142	0	For
NEW ECONOMY FUND	957,477	0	For
Prudential/PGIM	675,601	0	For
JPMorgan	580,480	0	For
HARBOR FUNDS	474,913	0	For
American Century	419,067	0	For
AllianceBernstein	404,858	0	For
BlackRock	340,338	0	For
AB DISCOVERY GROWTH FUND, INC.	291,102	0	For
Federated Hermes	238,053	0	For
BNY Mellon	176,721	0	For
Victory Capital	173,390	0	For
Equitable	143,848	0	For
FRANKLIN STRATEGIC SERIES	132,778	0	For
ALPS ETF Trust	96,492	0	For
Principal	87,095	0	For
Lord Abbett	83,119	0	For
Bridge Builder Trust	81,840	0	For
Eaton Vance	81,652	0	For
Allspring	78,965	0	For
Brighthouse	33,524	28,720	For
OPTIMUM FUND TRUST	60,861	0	For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

5. RATIFICATION OF THE SELECTION OF DELOITTE ACCOUNTANTS B.V. AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026 BY THE AUDIT COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 91,502,639AGAINST: 4,618

NewAmsterdam Pharma Company N.V.’s own tally for this item (“Proposal 4. The Company's shareholders ratified the selection by the Company's Audit Committee of Deloitte Accountants B.V.”): 91,502,639 for, 4,618 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 116,641,656 outstanding shares: 78% for, 0.1% against (78% of the company cast a for/against vote).

The 55 asset managers below cast 100% of the shares they voted on this item FOR (24,905,221 for, 0 against).

FOR 99.8%

FOR: 24,905,221 (99.9%)ABSTAIN: 28,720 (0.1%)

Largest asset managers voting on “RATIFICATION OF THE SELECTION OF DELOITTE ACCOUNTANTS B.V. AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIR” at NewAmsterdam Pharma Company N.V., 2025-2026
Asset manager	For	Abstain	Vote
Capital Group	9,331,713	0	For
Fidelity	5,216,459	0	For
Vanguard	3,200,642	0	For
Columbia Threadneedle	982,142	0	For
NEW ECONOMY FUND	957,477	0	For
Prudential/PGIM	675,601	0	For
JPMorgan	580,480	0	For
HARBOR FUNDS	474,913	0	For
American Century	419,067	0	For
AllianceBernstein	404,858	0	For
BlackRock	340,338	0	For
AB DISCOVERY GROWTH FUND, INC.	291,102	0	For
Federated Hermes	238,053	0	For
BNY Mellon	176,721	0	For
Victory Capital	173,390	0	For
Equitable	143,848	0	For
FRANKLIN STRATEGIC SERIES	132,778	0	For
ALPS ETF Trust	96,492	0	For
Principal	87,095	0	For
Lord Abbett	83,119	0	For
Bridge Builder Trust	81,840	0	For
Eaton Vance	81,652	0	For
Allspring	78,965	0	For
Brighthouse	33,524	28,720	For
OPTIMUM FUND TRUST	60,861	0	For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

6. Approval of the NewAmsterdam Pharma Company N.V. 2026 Employee Stock Purchase Plan.

COMPENSATION

Combines 2 wordings of this item as funds reported it.

99.8% fund support · no official result

FOR 99.8%

The 55 asset managers below cast 99.8% of the shares they voted on this item FOR (24,879,205 for, 28,720 against).

FOR: 24,879,205 (99.9%)AGAINST: 28,720 (0.1%)

Largest asset managers voting on “Approval of the NewAmsterdam Pharma Company N.V. 2026 Employee Stock Purchase Plan.” at NewAmsterdam Pharma Company N.V., 2025-2026
Asset manager	For	Against	Vote
Capital Group	9,331,713	0	For
Fidelity	5,216,459	0	For
Vanguard	3,200,642	0	For
Columbia Threadneedle	982,142	0	For
NEW ECONOMY FUND	957,477	0	For
Prudential/PGIM	675,601	0	For
JPMorgan	580,480	0	For
HARBOR FUNDS	474,913	0	For
American Century	419,067	0	For
AllianceBernstein	404,858	0	For
BlackRock	340,338	0	For
AB DISCOVERY GROWTH FUND, INC.	291,102	0	For
Federated Hermes	238,053	0	For
BNY Mellon	176,721	0	For
Victory Capital	173,390	0	For
Equitable	143,848	0	For
FRANKLIN STRATEGIC SERIES	132,778	0	For
ALPS ETF Trust	96,492	0	For
Principal	87,095	0	For
Lord Abbett	83,119	0	For
Bridge Builder Trust	81,840	0	For
Eaton Vance	81,652	0	For
Allspring	78,965	0	For
Brighthouse	33,524	28,720	For
OPTIMUM FUND TRUST	60,861	0	For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

7. ADOPTION OF THE DUTCH STATUTORY ANNUAL ACCOUNTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025.

CORPORATE GOVERNANCE

100% fund support · no official result

FOR 99.8%

The 54 asset managers below cast 100% of the shares they voted on this item FOR (24,873,000 for, 0 against).

FOR: 24,873,000 (99.9%)ABSTAIN: 28,720 (0.1%)

Largest asset managers voting on “ADOPTION OF THE DUTCH STATUTORY ANNUAL ACCOUNTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025.” at NewAmsterdam Pharma Company N.V., 2025-2026
Asset manager	For	Abstain	Vote
Capital Group	9,331,713	0	For
Fidelity	5,216,459	0	For
Vanguard	3,200,642	0	For
Columbia Threadneedle	982,142	0	For
NEW ECONOMY FUND	957,477	0	For
Prudential/PGIM	675,601	0	For
JPMorgan	580,480	0	For
HARBOR FUNDS	474,913	0	For
American Century	419,067	0	For
AllianceBernstein	404,858	0	For
BlackRock	340,338	0	For
AB DISCOVERY GROWTH FUND, INC.	291,102	0	For
Federated Hermes	238,053	0	For
BNY Mellon	176,721	0	For
Victory Capital	173,390	0	For
Equitable	143,848	0	For
FRANKLIN STRATEGIC SERIES	132,778	0	For
ALPS ETF Trust	96,492	0	For
Principal	87,095	0	For
Lord Abbett	83,119	0	For
Bridge Builder Trust	81,840	0	For
Eaton Vance	81,652	0	For
Allspring	78,965	0	For
Brighthouse	33,524	28,720	For
OPTIMUM FUND TRUST	60,861	0	For

Showing the 25 largest of 54 asset managers. See all 54 in the interactive database.

8. DISCHARGE FROM LIABILITY FOR THE COMPANY'S DIRECTORS WITH RESPECT TO THE PERFORMANCE OF THEIR DUTIES DURING THE FISCAL YEAR ENDED DECEMBER 31, 2025.

CORPORATE GOVERNANCEMajority of the votes cast: yes

99% Majority: yes · of votes cast

FOR 99%

FOR: 85,229,605AGAINST: 1,105,840

NewAmsterdam Pharma Company N.V.’s own tally for this item (“Proposal 2. The Company's shareholders approved the discharge from liability for the Company's directors with respect to the performance of their duties during the fiscal year ended December 31, 2025.”): 85,229,605 for, 1,105,840 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 116,641,656 outstanding shares: 73% for, 1.0% against (74% of the company cast a for/against vote).

The 54 asset managers below cast 100% of the shares they voted on this item FOR (24,873,000 for, 0 against).

FOR 99.8%

FOR: 24,873,000 (99.9%)ABSTAIN: 28,720 (0.1%)

Largest asset managers voting on “DISCHARGE FROM LIABILITY FOR THE COMPANY'S DIRECTORS WITH RESPECT TO THE PERFORMANCE OF THEIR DUTIES DURING TH” at NewAmsterdam Pharma Company N.V., 2025-2026
Asset manager	For	Abstain	Vote
Capital Group	9,331,713	0	For
Fidelity	5,216,459	0	For
Vanguard	3,200,642	0	For
Columbia Threadneedle	982,142	0	For
NEW ECONOMY FUND	957,477	0	For
Prudential/PGIM	675,601	0	For
JPMorgan	580,480	0	For
HARBOR FUNDS	474,913	0	For
American Century	419,067	0	For
AllianceBernstein	404,858	0	For
BlackRock	340,338	0	For
AB DISCOVERY GROWTH FUND, INC.	291,102	0	For
Federated Hermes	238,053	0	For
BNY Mellon	176,721	0	For
Victory Capital	173,390	0	For
Equitable	143,848	0	For
FRANKLIN STRATEGIC SERIES	132,778	0	For
ALPS ETF Trust	96,492	0	For
Principal	87,095	0	For
Lord Abbett	83,119	0	For
Bridge Builder Trust	81,840	0	For
Eaton Vance	81,652	0	For
Allspring	78,965	0	For
Brighthouse	33,524	28,720	For
OPTIMUM FUND TRUST	60,861	0	For

Showing the 25 largest of 54 asset managers. See all 54 in the interactive database.

9. EXTENSION OF AUTHORIZATION FOR THE BOARD OF DIRECTORS TO LIMIT OR EXCLUDE PRE-EMPTION RIGHTS.

SHAREHOLDER RIGHTS AND DEFENSESMajority of the votes cast: yes

67% Majority: yes · of votes cast

FOR 67%AGAINST 33%

FOR: 57,890,766AGAINST: 28,450,917

NewAmsterdam Pharma Company N.V.’s own tally for this item (“Proposal 7. The Company's shareholders approved the extension of authorization for the Board of Directors to limit or exclude pre-emption rights, for a five-year period ending June 2, 2031.”): 57,890,766 for, 28,450,917 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 116,641,656 outstanding shares: 49.6% for, 24% against (74% of the company cast a for/against vote).

The 54 asset managers below cast 31% of the shares they voted on this item FOR (7,666,201 for, 17,235,519 against).

FOR 31%AGAINST 69%

FOR: 7,666,201 (30.8%)AGAINST: 17,235,519 (69.2%)

Largest asset managers voting on “EXTENSION OF AUTHORIZATION FOR THE BOARD OF DIRECTORS TO LIMIT OR EXCLUDE PRE-EMPTION RIGHTS.” at NewAmsterdam Pharma Company N.V., 2025-2026
Asset manager	For	Against	Vote
Capital Group	1,638,968	7,692,745	Against
Fidelity	5,185,849	30,610	For
Vanguard	134,879	3,065,763	Against
Columbia Threadneedle	0	982,142	Against
NEW ECONOMY FUND	0	957,477	Against
Prudential/PGIM	0	675,601	Against
JPMorgan	580,480	0	For
HARBOR FUNDS	0	474,913	Against
American Century	0	419,067	Against
AllianceBernstein	0	404,858	Against
BlackRock	0	340,338	Against
AB DISCOVERY GROWTH FUND, INC.	0	291,102	Against
Federated Hermes	0	238,053	Against
BNY Mellon	0	176,721	Against
Victory Capital	0	173,390	Against
Equitable	13,851	129,997	Against
FRANKLIN STRATEGIC SERIES	0	132,778	Against
ALPS ETF Trust	0	96,492	Against
Principal	0	87,095	Against
Lord Abbett	83,119	0	For
Bridge Builder Trust	0	81,840	Against
Eaton Vance	0	81,652	Against
Allspring	0	78,965	Against
Brighthouse	0	62,244	Against
OPTIMUM FUND TRUST	0	60,861	Against

Showing the 25 largest of 54 asset managers. See all 54 in the interactive database.

10. INSTRUCTION TO DELOITTE ACCOUNTANTS B.V. AS THE COMPANY'S EXTERNAL AUDITOR OF THE COMPANY'S DUTCH STATUTORY ANNUAL ACCOUNTS AND DUTCH STATUTORY BOARD REPORT FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 91,502,529AGAINST: 4,636

NewAmsterdam Pharma Company N.V.’s own tally for this item (“Proposal 3. The Company's shareholders approved the instruction to Deloitte Accounts B.V.”): 91,502,529 for, 4,636 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 116,641,656 outstanding shares: 78% for, 0.1% against (78% of the company cast a for/against vote).

The 54 asset managers below cast 100% of the shares they voted on this item FOR (24,873,000 for, 0 against).

FOR 99.8%

FOR: 24,873,000 (99.9%)ABSTAIN: 28,720 (0.1%)

Largest asset managers voting on “INSTRUCTION TO DELOITTE ACCOUNTANTS B.V. AS THE COMPANY'S EXTERNAL AUDITOR OF THE COMPANY'S DUTCH STATUTORY AN” at NewAmsterdam Pharma Company N.V., 2025-2026
Asset manager	For	Abstain	Vote
Capital Group	9,331,713	0	For
Fidelity	5,216,459	0	For
Vanguard	3,200,642	0	For
Columbia Threadneedle	982,142	0	For
NEW ECONOMY FUND	957,477	0	For
Prudential/PGIM	675,601	0	For
JPMorgan	580,480	0	For
HARBOR FUNDS	474,913	0	For
American Century	419,067	0	For
AllianceBernstein	404,858	0	For
BlackRock	340,338	0	For
AB DISCOVERY GROWTH FUND, INC.	291,102	0	For
Federated Hermes	238,053	0	For
BNY Mellon	176,721	0	For
Victory Capital	173,390	0	For
Equitable	143,848	0	For
FRANKLIN STRATEGIC SERIES	132,778	0	For
ALPS ETF Trust	96,492	0	For
Principal	87,095	0	For
Lord Abbett	83,119	0	For
Bridge Builder Trust	81,840	0	For
Eaton Vance	81,652	0	For
Allspring	78,965	0	For
Brighthouse	33,524	28,720	For
OPTIMUM FUND TRUST	60,861	0	For

Showing the 25 largest of 54 asset managers. See all 54 in the interactive database.

11. Approve Qualified Employee Stock Purchase Plan

CAPITAL STRUCTURE

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (257,023 for, 0 against).

FOR: 257,023 (100.0%)

Largest asset managers voting on “Approve Qualified Employee Stock Purchase Plan” at NewAmsterdam Pharma Company N.V., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Eversept Partners, LP	224,802	0	0	0	For
Eleva Capital SAS	32,221	0	0	0	For

Largest NewAmsterdam Pharma Company N.V. shareholders voting in 2025-2026

Ranked by the number of NewAmsterdam Pharma Company N.V. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 116,641,656 shares outstanding at the time of that meeting.

Top NewAmsterdam Pharma Company N.V. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Capital Group	19.11%
2	Fidelity	9.97%
3	RA CAPITAL MANAGEMENT, L.P.	8.18%
4	FCPM III SERVICES B.V.	7.89%
5	Bain Capital Life Sciences Investors, LLC	4.86%
6	DEERFIELD MANAGEMENT COMPANY, L.P.	3.66%
7	VIKING GLOBAL INVESTORS LP	3.60%
8	Wellington	3.17%
9	Janus Henderson	2.98%
10	Polar Capital Holdings Plc	2.95%

Reported NewAmsterdam Pharma Company N.V. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

NewAmsterdam Pharma Company N.V. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Frazier Lifesciences Sponsor LLC and affiliates	14.75%	DEF14A
Capital World Investors	10.45%	13G
RA Capital Healthcare Fund, L.P.	10.16%	DEF14A
Frazier Life Sciences Public Fund, L.P.	8.94%	13D
Entities affiliated with Forbion	7.99%	DEF14A
FMR (Fidelity)	7.52%	13F
Entities affiliated with Bain Capital Life Sciences Investors, LLC	6.35%	DEF14A
James N. Topper, M.D., Ph.D.	6.28%	DEF14A
FMR LLC	5.50%	DEF14A
Wellington Management	4.39%	13F

Percentages above are of 116,641,656 shares outstanding, as reported by NewAmsterdam Pharma Company N.V. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from NewAmsterdam Pharma Company N.V.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At NewAmsterdam Pharma Company N.V.'s shareholder meeting held 2026-06-02, in the 2025-2026 proxy season, 188 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,570 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Non-binding, advisory vote to approve the 2025 compensation of named executive officers. — FOR was 94% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: NewAmsterdam Pharma Company N.V.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-03.

NewAmsterdam Pharma Company N.V. proxy season coverage: 2024-2025 · 2025-2026 (this page).